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Tacrolimus is the milestone in pediatric liver transplant immunosuppression. Despite close 
monitoring, fluctuations in tacrolimus blood levels affect safety and efficacy of 
immunosuppressive treatments. Identifying the factors related to the variability in tacrolimus 
exposure may be helpful in tailoring the dose. The aim of the present study was to 
characterize the clinical, pharmacological, and genetic variables associated with tacrolimus 
systemic exposure in pediatric liver transplant patients. 
De-novo transplant patients with a survival of more than one month were considered for 
inclusion and genotyped for CYP3A5. Peri-transplant clinical factors and laboratory 
covariates, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
hematocrit, and tacrolimus pre-dose steady-state blood concentrations collected 12 h after 
tacrolimus dose (C0), were recorded retrospectively between one month and two years post-
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factors and the log-transformed tacrolimus dose-normalized C0 (logC0/D). Bootstrapping 
was used to internally validate the final model. External validation was performed in an 
independent group of patients that matched the original population. The developed LME 
model described that logC0/D increases as time post-transplant and ALT values increase 
(β=0.019, 95% CI, 0.010-0.028 and β=0.00030, 95% CI, 0.00002-0.00056, respectively), 
whereas it is significantly lower in graft CYP3A5-expressers compared to non-expressers [β= 
-0.349, 95% CI, -0.631-(-0.062)]. 
Conclusions: Donor CYP3A5 genotype, time post-transplant and, alanine aminotransferase 
values are associated with tacrolimus disposition between one month and two years post-
transplant. A better understanding of tacrolimus exposure is essential to minimize the 




Tacrolimus has become the cornerstone in immunosuppression in pediatric and adult liver 
transplant recipients to prevent allograft rejection. This calcineurin inhibitor has a narrow 
therapeutic index and presents large inter- and intra-individual pharmacokinetic variability (1, 
2). In order to optimize its efficacy and minimize the occurrence of adverse events, 
therapeutic drug monitoring (TDM) is regularly performed in clinical practice based on 
trough concentrations (C0) determined before the next dose of tacrolimus (1). Trough 
concentrations have been selected as a measure of systemic exposure that correlates with 
clinical outcome (graft rejection and tacrolimus toxicity) (3). However, C0-based therapeutic 
ranges in children are defined based on adult clinical data (2), with subsequent empirical 
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Although the optimization of immunosuppressive therapies and the improvements in surgical 
procedures have contributed to longer overall and graft survival in pediatric liver 
transplantation, clinical issues, such as acute rejection and adverse drug reactions to 
tacrolimus, confer morbidity and mortality (1, 4). Moreover, previous reports have described 
a significant association between variability in tacrolimus C0 and the development of acute 
rejection and adverse drug reactions (1, 5-7). Furthermore, other factors including time post-
transplant, body weight, hematocrit, age, liver function parameters, and type of graft 
contribute to its pharmacokinetic variability in pediatric liver transplant patients (1, 8-16). 
Different polymorphisms of cytochrome P450 enzymes, especially in CYP3A5, affect 
tacrolimus clearance. This enzyme plays an important role in the metabolism of tacrolimus, 
and is mainly expressed in liver and intestine. A polymorphism in intron 3 of CYP3A5 
(CYP3A5*3 allele) produces an abnormally spliced mRNA with a premature stop codon 
resulting in the absence of the CYP3A5 enzyme (17). Several studies have described higher 
tacrolimus trough concentrations in adult patients carrying the CYP3A5*3 allele (non-
expressers) compared to the expressers (CYP3A5*1 carriers) (18-20). In addition, some 
studies have reported this association in Asian and European pediatric patients (9-12, 21-23). 
However, the behavior of tacrolimus variability in Latin-American pediatric liver transplant 
recipients is unknown and reports regarding safety and efficacy of immunosuppressive 
regimens are scarce (24).  
For all mentioned, we aimed to evaluate the impact of donor and recipient genetic 
polymorphisms in the CYP3A5 enzyme on tacrolimus C0 and to identify and characterize 
different clinical and biochemical variables associated with tacrolimus exposure after oral 
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1. Methods 
This study is a retrospective, single-center cohort study conducted in accordance to the 
Helsinki Declaration at Hospital de Pediatría JP Garrahan (Buenos Aires, Argentina) after 
approval by the Institutional Review Board (Protocol #740). Written informed consent was 
obtained from parents or guardians. 
 
Study Population 
This study is part of a previous one that aimed to identify peri-transplant predictors of acute 
rejection and factors related to the risk of tacrolimus adverse drug reactions in pediatric liver 
transplant patients (6) in the context of the implementation of a new immunosuppressive 
protocol. Pediatric de-novo liver allograft recipients less than 18 years old at the time of 
transplantation were included during the period in which the CYP3A5 genotyping technique 
was available at the Hospital de Pediatría JP Garrahan. Patients included in the present 
analysis had at least four tacrolimus trough concentrations during the study period. Exclusion 
criteria included: less than 1 month of post-transplant survival, re-transplantation, combined 
or multivisceral transplants, interval of administration of tacrolimus other than every 12 h, 
and inappropriate follow-up or noncompliance, as previously defined (24). In addition, 
tacrolimus C0 levels obtained at times at which the patient was receiving simultaneous 
administration of azoles, macrolides, antiepileptic drugs, and/or calcium channel blockers, 
were excluded from the analysis. Follow-up data were collected between 1 month post-
transplant and 2 years. All data were collected from the medical and nursing records, and a 
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Immunosuppressive therapy 
Tacrolimus (0.1 mg/kg/day) was initiated after reperfusion and kidney function 
normalization, administered in monotherapy with anti-CD25 induction (basiliximab) on day 0 
and day 4, or in combination with corticosteroids and/or mycophenolate mofetil according to 
kidney and liver function (25), as depicted in Table 1. Concomitant drugs were 
sulfamethoxazole-trimethoprim, magnesium supplements, omeprazole (in all patients), 
acyclovir, and additional antibiotics, if needed.  
 
Tacrolimus monitoring 
For the analysis we used retrospective routine therapeutic drug monitoring (whole-blood 12-h 
tacrolimus C0). Patients were given oral tacrolimus (Prograft®, Astellas Laboratory, 
Killorglin, Co. Kerry, Ireland) twice daily. Data (tacrolimus doses, C0s, weight) were 
recorded after 30 days post-transplantation and every day during hospitalization and/or on 
out-patient visits for 2 years. At all times that a blood sample was obtained for assessment of 
tacrolimus C0, a complete blood sample test was performed including liver and renal function 
tests, hematocrit and hemoglobin levels. Characteristics of the patients enrolled in the study 
are presented in Table 1.  
Tacrolimus trough concentrations were quantified using the chemiluminescent microparticle 
immunoassay (CMIA) (Architect; Abbott, Chicago, IL). Whole blood quality controls 
(Lyphochek Whole Blood Immunosuppressant; Bio-Rad, Irvine, CA) were daily assessed for 
assay acceptance. In addition, specimens were routinely assessed as part of an international 
proficiency testing program for the external quality control of tacrolimus (26). Total 
imprecision was less than 8%, and quality control values lied in the range of +/-2SD. 
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first 6 months, 5-7ng/mL during the next 6 months, and 5ng/mL after the first year post-
transplant(27, 28). 
 
Biochemical, clinical, and genetic factors 
Peri-transplant and post-transplant variables were studied including: demographic features: 
age, weight at transplant, gender, and primary diagnosis; biochemical values: hematocrit, 
albumin, serum creatinine, uremia, total bilirubin, liver function markers (aspartate 
transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and gamma-
glutamyl transpeptidase (GGT) activity); transplant features: type of graft (partial graft from 
a living or deceased donor vs. a whole graft from a deceased donor), type of donor (deceased 
vs. living donor), and days post-transplant; clinical status: Epstein bar virus and 
cytomegalovirus infections; and genotyping: CYP3A5*3 polymorphism in donors and 
recipients. CYP3A5 genotyping procedure was previously described (6).  
In addition, we registered concomitant immunosuppressive agents such as steroids (at least 
30 consecutive days), azathioprine, mycophenolate mofetil, and sirolimus.  
 
Relationship between tacrolimus C0 and predictor parameters 
A linear mixed effect (LME) model was used to investigate the influence of CYP3A5 
genotype, pharmacological factors, and clinical and laboratory parameters on log-transformed 
tacrolimus dose-normalized C0 concentrations (logC0/D).  
 
Model development  
The total dataset was randomly split into a model-building and a validation dataset. The 
model was initiated with the development of the base model in the model-building dataset to 
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intercept, slope with and without inter-model correlation) and the best model was selected 
based on the Akaike information criterion (AIC). Both continuous (time post-transplant, 
hematocrit, AST, ALT, ALP, and GGT activity) and categorical variables (administration of 
steroids and/or mycophenolate sodium or mofetil, Epstein-Barr virus infection, 
cytomegalovirus infection, type of donor, type of graft, and CYP3A5*3 polymorphism in 
donors and recipients) were considered in the analysis.  
Covariates associated with a p value < 0.05 in the univariate analysis, and were therefore 
considered clinically relevant and biologically plausible, were included in the multivariate 
intermediate model. The final model was selected using a backward stepwise process based 
on the AIC. All statistical analyses and graphs were performed with RStudio Version 
0.99.486, 2015, Inc (29, 30) using R (R Core Team, 2015), lme4 (31), and nlme (32). 
Finally, all assumptions were checked in the final model, including linearity, absence of co-
linearity, homoscedasticity, normality of residuals, absence of influential data points, and 
independence (30). 
 
Model evaluation and external validation.  
Once the final model was defined, a bootstrap was used to evaluate the stability and accuracy 
and to calculate the 2.5-97.5 percentiles of parameter estimates. The median values of the 
bootstrap parameters were compared to the values of the final model.  
The performance of the model was visually assessed by comparing plots of the predicted 
concentration (Cpred) and the observed concentration (Cobs) to assess for bias (a systematic 
upward or downward deviation from the line of unity in these plots) and imprecision (a high 
degree of scatter of data points around the line of unity). 
External validation was performed in the validation dataset that matched the data used for 
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through calculation of the mean error (ME), the mean relative error (MRE), and the relative 
root mean squared error (RMSE) as previously reported (33). 
 
Results 
Overall, 89 patients were considered for inclusion based on the implementation of a new 
immunosuppressive protocol in 2010 and according to the availability of data as detailed 
below. Patients were excluded because of a survival shorter than 1 month (n=5), unavailable 
medical records (n=4), re-transplantation during the first month after surgery (n=2), absence 
of pharmacokinetic and clinical data (n=5), absence of genotyping data from donors and/or 
recipients due to limited amount of DNA or no availability of formalin-fixed paraffin 
embedded liver tissue (n=14), and non-adherence as previously defined (6) (n=6). Therefore, 
53 patients were finally included in the analysis. Demographics, laboratory parameters, and 
clinical characteristics of the patients included in the building (n=40) and validation (n=13) of 
the dataset are shown in Table 1. 
CYP3A5 polymorphism distribution in both donors and receptors included in this study is 
reported in Table S1 (Supporting Table 1). The genotype frequencies of the CYP3A5 
polymorphism did not deviate from the Hardy–Weinberg equilibrium (p > 0.5) as previously 
reported (6). According to the report of the Clinical Pharmacogenetics Implementation 
Consortium (34), the estimated allele frequency of CYP3A5*1 and *3 in our population was 
similar to that reported for the Latin American cohort of patients analyzed in the mentioned 
guideline. Specifically, our population showed an allele frequency of 0.254 and 0.746 for the 
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A base model was built using 824 tacrolimus trough concentrations obtained from the 
patients included in the model-building group. Random effects were included in the intercept 
for inter-individual variability and the slope for the effect of time post-transplant with a 
correlation between them.  
Univariate analysis showed a significant linear association between logC0/D and ALT values, 
time post-transplant, total bilirubin values, donor CYP3A5 polymorphism, and Epstein Barr 
Virus (EBV) infection status (p<0.05). All covariates significantly related to logC0/D are 
listed in Table 2. The positive associations between logC0/D and time post-transplant and 
ALT are shown in Figure 1 A and B, respectively. The figures show an increase in logC0/D 
with time post-transplant or with liver dysfunction assessed by ALT. As depicted in Figure 1 
C, logC0/D was lower in patients with a CYP3A5-expresser graft compared to non-
expressers (p<0.05). In more detail, Figure 1 D shows the bivariate model of logC0/D 
according to time post-transplant and donor CYP3A5 genotype. Patients with CYP3A5 non-
expresser grafts presented significantly higher logC0/D compared to CYP3A5 expressers 
between one month and two years post transplantation.  
After backwards elimination, the best multivariate model describing tacrolimus exposure 
retained the following covariates that independently correlate with logC0/D: time post-
transplantation, alanine aminotransferase values and donor CYP3A5 expression. Table 3 
summarizes the final model estimates. Visual inspection of residual plots did not reveal any 
obvious deviations from homoscedasticity or normality (Supporting Figure S1).  The 
predicted concentrations as a function of the observed concentrations of tacrolimus showed 
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The internal validation of the final model by bootstrapping (1000 successful runs) gave 
satisfactory results as shown in Table 3. Moreover, in the external validation, the predictive 
performance of the final model was successfully assessed: the mean error (ME) was 0.213, 
the mean relative error (MRE) was 2.05%, and precision, expressed as the relative root mean 
squared error (RMSE) was 15.4% for the predictive model.  
 
Discussion 
In this study, for the first time in a Latin-American pediatric liver transplant population, we 
identified different factors that significantly influence tacrolimus exposure. We developed 
and validated a model that showed a positive association between log-transformed tacrolimus 
dose-normalized trough concentrations and ALT values as well as time post-transplant, while 
a negative association with donor CYP3A5 expression (expressers vs. non-expressers) was 
found between 1 month and 2 years post-transplantation.  
Liver function tests, ALT and AST, are traditional markers of acute liver damage secondary 
to different events including acute rejection episodes, viral infections, and/or liver fibrosis 
(35). As 98-99% of tacrolimus is metabolized in the liver (36), it is expected that tacrolimus 
C0 increases with liver dysfunction. Previously, apparent clearance was found to decrease 
exponentially with the increase of AST in adult transplant patients (35). In our study, elevated 
ALT levels, compatible with impaired liver function, positively correlated with logC0/D due 
to a deficit in tacrolimus metabolism. 
Few studies have detected a relationship between tacrolimus exposure and time post-
transplant (11, 16). In our case, we observed that time post-transplant was retained in the final 
model and the ratio logC0/D increased with time, in line with a reduction in tacrolimus doses 
(data not shown). In adult transplant patients, reduced tacrolimus dose requirements have 
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explained by a decrease in tacrolimus clearance due to drug-drug interactions, increased 
bioavailability over time, or both (12, 40). Regarding drug-drug interactions, introduction or 
discontinuation of steroids may play an important role. The concurrent use of tacrolimus with 
mild CYP3A inducers, such as prednisone, may result in decreased tacrolimus trough 
concentrations whereas the discontinuation of steroids may result in an increased tacrolimus 
exposure (41). In our study, we registered the administration of steroids in the 
immunosuppressive maintenance treatment. We tested for the significance of concomitant 
steroids in tacrolimus logC0/D but it was not retained in the final model (p>0.05, Table 3). 
Thus, we were not able to confirm a drug-drug interaction effect of steroids in tacrolimus 
pharmacokinetics over time. On the other hand, tacrolimus largely binds to red blood cells 
and plasma proteins. Thus, the increase over time in oral bioavailability may potentially be 
due to an increased hematocrit and albumin concentration (10, 12, 42). In our study, we 
tested for the significance of hematocrit in tacrolimus C0 and did not find a significant 
relation (p>0.05, Table 2) to confirm the change of tacrolimus clearance over time. 
Nevertheless, the mechanisms responsible for the change in apparent clearance over time are 
only partly known (38-40) and further studies are required (12). 
The metabolism of tacrolimus largely occurs in the liver. CYP3A5 plays a more dominant 
role in the metabolism of tacrolimus than CYP3A4 (43) and has a significant effect on 
tacrolimus pharmacokinetics in adult and pediatric transplant patients (10-12, 18, 21, 22, 44, 
45). Specifically in liver transplantation, it has been reported that donor CYP3A5 genotype 
has a more dominant effect than the recipient genotype on tacrolimus pharmacokinetics (10, 
11, 18, 21, 22, 45). This result implies that after day 30 post-transplant, recipients of a graft 
expressing CYP3A5 have a lower logC0/D compared to recipients of a non-expresser graft. 
Therefore, higher tacrolimus doses are required in patients with grafts carrying CYP3A5*1 
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post transplantation. In these cases, therapeutic drug monitoring is performed as a tool to aid 
tacrolimus titration until reaching the target range. In agreement with our results, others 
reported that donor CYP3A5 expression significantly decreased tacrolimus C0/D due to a 
30% increase in tacrolimus clearance in a Japanese pediatric liver transplant population (11) 
and that tacrolimus daily dose requirement was higher among French children who received a 
liver expressing CYP3A5 compared with those with a CYP3A5*3 liver (21). The association 
between donor CYP3A5 genotype and tacrolimus disposition was also reported specifically 
on the first day after transplantation pediatric liver (46). On the other hand, considering the 
effect of the recipient CYP3A5-expression stratification we observed no association with 
tacrolimus exposure in our cohort of patients. However, previous studies in different 
populations did describe this association. In this sense Caucasian pediatric liver transplant 
recipients with CYP3A5 expression presented with an increased apparent clearance of 
tacrolimus compared with non-expressers (12). Furthermore, studies in Chinese pediatric 
liver transplant patients reported that CYP3A5 genotyping both in recipients and donors was 
necessary to establish a personalized tacrolimus dosage regimen (22). Therefore, donor 
genotype in addition to the patient genotype may play an important role in determining the 
tacrolimus pharmacokinetic response but results varied among studied populations. This 
highlights the necessity of further studies on the relationship between tacrolimus exposure 
and pharmacogenetics in both donors and liver pediatric transplant recipients.  
Some covariates identified as influential on tacrolimus pharmacokinetics were not retained in 
our final model. One of the most important pharmacokinetic properties of tacrolimus is its 
high binding capacity to red blood cells. Several pharmacokinetic studies have reported a 
significant effect of hematocrit on tacrolimus dose requirements (10, 14). This effect was not 
observed in the present population, which may be explained in part by the partial recovery of 
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hematocrit is observed and multiple transfusions are required. The type of donor (living 
donor/deceased donor) was tested for potential significant association to tacrolimus C0 based 
on a potential impact of regeneration of the graft (liver) leading to improvement of hepatic 
function(47). Nonetheless, this variable was not significantly associated with tacrolimus 
exposure measured as C0 as shown in Table 2. 
There are some limitations to be acknowledged in this study. First, because of its 
retrospective nature, it has all the limitations inherent to this type of descriptive study. 
Second, the area under the blood concentration-time curve (AUC) is expected to be a better 
marker of systemic exposure to tacrolimus than C0 (2); however, the AUC is difficult to 
obtain due to practical and ethical reasons in the pediatric population. Nevertheless, in 
children tacrolimus TDM is based on monitoring C0. Therefore, our results should be 
interpreted with caution. Third, we focused on the period after 30 days post-transplant in 
order to avoid the variability produced by hemodynamic alterations, interruption of doses, 
and different frequency intervals of tacrolimus administration. Finally, we also acknowledge 
that one of the reasons of the limited number of studied patients was the discontinuation of 
the genotyping technique due to reagents unavailability. 
The starting dose of tacrolimus is usually based on bodyweight and then adjusted by means 
of therapeutic drug monitoring. Recently, a model was developed to predict the individual 
starting dose of tacrolimus in pediatric renal transplantation and the final model included 
bodyweight (48). However, limited information is available in pediatric liver transplant 
patients. Therefore, our study provides novel information about tacrolimus dosing based on 
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After external validation, this model could be used in clinical practice to make dosage 
recommendations accounting for the liver enzyme levels (ALT), genetics, and time post-
transplant-dependent change in the log-C0/D of tacrolimus. For instance, we may assume two 
random patients in our study population with a body weight of 16.3 kg. The ALT level (UI/L) 
of Patient 1 is 1200 who underwent liver transplant 3.3 months before, whereas the ALT 
level in Patient 2 is 40 UI/L after receiving a liver transplant 9.3 months earlier. None of 
them is a graft expresser of CYP3A5. If tacrolimus trough concentrations have to be 
maintained at 5ng/ml, we could use the present model to calculate the tacrolimus doses. 
According to our model, the calculated dose for the first child would be 0.35 mg bid, while 
for the second child it would be 1.11 mg bid. This is in line with a setting in which lower 
tacrolimus doses are recommended in liver dysfunction to avoid systemic accumulation. If 
both patients have ALT levels of 40 UI/L, underwent surgery 4 months previously,  and 
Patient 1 has a non-expresser graft while Patient 2 has an expresser graft, tacrolimus doses 
would be 0.6 mg bid and 1.7 mg bid, respectively. 
In conclusion, in the present report we have developed a model to describe tacrolimus 
pharmacokinetics in children who underwent liver transplantation. This final LME model 
presented a suitable performance and predictive ability to adequate tacrolimus doses in future 
patients in order to minimize the occurrence of an out-of-range therapeutic window that may 
lead to adverse drug reactions or acute rejection. The results of this study may be used in the 
clinical setting in conjunction with therapeutic drug monitoring and may contribute to the 
development of programs to optimize tacrolimus dosing, taking into account not only patient 
body weight but also time post-transplant, genotype, and liver function. 
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Figure legends 
 
Figure 1. Relation between Log-transformed dose normalized tacrolimus trough 
concentrations according to time post-transplantation (A), alanine aminotransferase values 
(B), and donor CYP3A5 genotype (C). Bivariate linear mixed effect model according to time 
post-transplant and donor CYP3A5 genotype. 
* p< 0.05 
Abbreviations: ALT: alanine aminotransferase; C0: tacrolimus trough concentrations; 
CYP3A5: donor CYP3A5 genotype (0: non-expressers, 1:expressers). 
Figure 2. Goodness of fit plot of the final model. Observed vs. individual predicted 
tacrolimus concentrations.  





Supporting information.  
 
Supporting Figure S1. Plots of the standardized residuals versus fitted values (A), histogram 
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Number of subjects 40 13 
Age (years)† ¶ 2.2 (0.5-17.6) 3.7 (0.8-12.2) 
Sex (female/male) 24/16 10/3 
Weight (kg)† ¶ 16.3 (6.0-75.0) 19 (6.8-74) 
Type of donor (deceased/living) 31/9 10/3 
Follow-up time (months)† ¶ 18.6 (1.3-25.9) 18.6 (1.4-30.9) 
Graft type (complete/technical variant) 17/23 2/11 
Primary Diagnosis Number (%) 
Biliary atresia 16 (40) 6 (46) 
Acute liver failure 9 (23) 2 (15) 
Cholestatic cirrhosis‡ 4 (10) 3 (23) 
Hepatic cirrhosis: autoimmune and 
cryptogenic 6 (15) 1 (8) 
Malignancies§ 3 (7) 1 (8) 
Metabolic disease: metabolic liver failure 2 (5) 0 (0) 
Immunosuppressive therapy 
Basiliximab (10 to 20 mg/doses at days 0 and 
4 after transplantation) 28 (70) 10 (77) 
Tacrolimus (0.1 mg/kg/day) 40 (100) 13 (100) 
Prednisone (1.25–3.75 mg/kg/day) 35 (88) 11 (86) 
Mycophenolate mofetil (20–40 mg/kg/day) 20 (50) 7 (54) 
Azathioprine (1-2 mg/kg/day) 3 (8) 2 (15) 
Sirolimus (0.1 mg/kg/day) 4 (10) 1 (8) 
Liver function and blood parameters¶ Mean (SD) 
AST (UI/L) 88.8 (120.5) 82.3 (100.9) 
ALT (UI/L) 135.1 (153.3) 120.6 (139.2) 
GGT (UI/L) 234.0 (305.4) 295.4 (346.4) 
Total bilirubin (mg/dL) 2.3 (1.8) 2.3 (4.5) 
Direct bilirubin (mg/dL) 0.9 (2.2) 2.3 (4.8) 
Albumin (g/dL) 3.6 (0.6) 3.4 (0.6) 
Hematocrit (%) 32.7 (4.6) 32.8 (5.1) 
Serum creatinine (mg/dL) 0.4 (0.2) 0.5 (0.2) 
Pharmacokinetic data ¶ Mean (SD) 
Total number of tacrolimus samples 824 352 
Number of samples per patient† 16 (4-71) 29 (4-48) 
Tacrolimus blood concentrations (ng/ml) 6.3 (2.6) 6.8 (2.7) 
Tacrolimus daily dose (mg) 2.6 (2.1) 2.9 (2.3) 
Tacrolimus daily dose normalized (mg/kg) 0.15 (0.10) 0.14 (0.10) 
Dose normalized tacrolimus trough 
concentration [(ng/ml)/(mg/kg)] 114.39 (96.99) 149.27 (122.75) 
Log-transformed dose normalized tacrolimus 
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Abbreviations: AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, 
gammaglutamyl transpeptidase. 
†Data are expressed as median (range). ‡Including Alagille syndrome, congenital hepatic 
fibrosis, and sclerosing cholangitis. §Including hepatoblastoma and hepatocellular carcinoma. 
¶ Continuous demographic data and clinical laboratory data recorded during the complete 
study period did not significantly differ between model-building and validation data sets 





Table 2. Univariate linear mixed models for the log-transformed dose-normalized tacrolimus 
trough concentrations in pediatric liver transplant patients 
 




   ALT (UI/L) 0.0005 0.0001 <0.001 
Hematocrit (%)  -0.0005 0.0043 0.90 
Total bilirubin (mg/dL)  0.032 0.012 0.01 
Immunosuppressive scheme 
   Co-administration of steroids and/or 
Mycophenolate mofetil/sodium (yes vs no) 0.115 0.043 0.01 
Clinical parameters 
   CMV infection (yes vs no) -0.094 0.095 0.33 
EBV infection (yes vs no) -0.152 0.061 0.01 
Time post-transplant (months) 0.023 0.004 <0.001 
Transplant variables 
   Type of donor (living vs deceased) -0.163 0.207 0.44 
Graft type (complete=1 vs technical variant=0) 0.143 0.171 0.41 
Genetic variables 
   Donor CYP3A5 polymorphism (expressers vs 
non-expressers) -0.413 0.168 0.02 
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Estimates (%SE) P value 2.5, 97.5 percentiles 
of the bootstrap 
 (Intercept) 4.424 (10.644) <0.001 4.186, 4.647 
Time post-transplant per month 0.019 (0.437) <0.001 0.010, 0.028 
ALT (UI/L) 0.00030 (0.014) 0.03 0.00002, 0.00056 
Donor CYP3A5 polymorphism 
(expressers vs non-expressers) 
-0.349 (13.840) 0.02 -0.631,-0.062 
Interaction term (Time*ALT) 0.00005 (0.002) 0.004 0.00001, 0.00008 
Random effects    
Random effect on subject 0.580  0.439, 0.708 
Random effect on slope 0.018  0.010, 0.025 
Correlation between random effects -0.852  -1.000, -0.645 
Residual variability 0.350  0.332, 0.369 
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